Brief: Cereno Scientific Signs CRO For Phase II Study With Drug Candidate CS1 In Rare Disease PAH

Cereno Scientific AB

14/01/2021 07:41

Jan 14 (Reuters) - Cereno Scientific AB  CRNOSb.TE :
    * CERENO SCIENTIFIC SIGNS CRO FOR PHASE II STUDY WITH DRUG
CANDIDATE CS1 IN RARE DISEASE PAH
    * SIGNED A LETTER OF INTENT WITH THE GLOBAL CONTRACT
RESEARCH
ORGANIZATION (CRO) WORLDWIDE CLINICAL TRIALS
    * CLINICAL TRIAL APPLICATION PROCESS FOR THE STUDY HAS BEEN
INITIATED AND THE STUDY START IS EXPECTED TO BE INITIATED IN
MID-2021

Source text for Eikon:  ID: 
Further company coverage:  CRNOSb.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))